Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +21.23% | +19.04% | +8.38% | +28.65% | +13.65% |
| Weighted Average Shares Diluted Growth | +21.23% | +19.04% | +8.38% | +28.65% | +13.65% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +19.82% | -11.73% | +54.07% | +60.72% | +46.17% |
| Book Value per Share Growth | +3.94% | -23.77% | +47.80% | +28.33% | +30.52% |
| Debt Growth | -100.00% | +44.84% | +243.20% | +355.29% | +0.00% |
| R&D Expense Growth | +15.74% | +24.66% | +14.16% | -14.27% | +2.51% |
| SG&A Expenses Growth | +27.94% | +12.98% | +22.78% | +18.26% | +111.28% |